Agar gel immunodiffusion analysis using baculovirus-expressed recombinant bovine leukemia virus envelope glycoprotein (gp51/gp30\(_{-}\))

Seong In Lim, Wooseog Jeong, Dong Seob Tark, Dong Kun Yang, Chang Hee Kweon*

National Veterinary Research and Quarantine Service, Anyang 430-757, Korea

Bovine leukemia virus (BLV) envelope glycoprotein (gp51/gp30\(_{-}\)), consisting of BLV gp51 and BLV gp30 that lacked its C-terminal transmembrane domain, was expressed in insect cells under the control of the baculovirus polyhedron promoter. Recombinant BLV gp51/gp30\(_{-}\) secreted from insect cells was determined by immunofluorescence, enzyme-linked immunosorbent and western blot assays using a BLV-specific monoclonal antibody and BLV-positive bovine antibodies. An agar gel immunodiffusion (AGID) test using gp51/gp30\(_{-}\) as the antigen for the detection of BLV antibodies in serum was developed and compared to traditional AGID, which uses wild type BLV antigen derived from fetal lamb kidney cells. AGID with the recombinant BLV gp51/gp30\(_{-}\) was relatively more sensitive than traditional AGID. When the two methods were tested with bovine sera from the field, the recombinant BLV gp51/gp30\(_{-}\) and traditional antigen had a relative sensitivity of 69.8% and 67.4%, respectively, and a relative specificity of 93.3% and 92.3%. These results indicated that the recombinant BLV gp51/gp30\(_{-}\) is an effective alternative antigen for the diagnosis of BLV infection in cattle.

Keywords: AGID, baculovirus expression, bovine leukemia virus, glycoproteins

Introduction

Bovine leukemia virus (BLV) is the viral agent of enzootic bovine leukemia (EBL) in cattle. With the exception of a few European countries, EBL is considered to have a worldwide distribution. Although the majority of infected cattle remain clinically asymptomatic, invisible losses in productivity have a significant economic impact on the dairy industry [4,24,26]. BLV is an oncogenic retrovirus of the Retroviridae family. Similar to other retroviruses, the envelope glycoprotein (Env) of BLV is the immunodominant protein in vivo [3,8,7,18]. The BLV env gene encodes a precursor protein that is processed into two subunits, gp51, the outer membrane subunit, and gp30, the transmembrane subunit, both of which are essential for viral infectivity [20, 28]. A variety of diagnostic tests have been developed for BLV, including PCR-based assays, agar gel immunodiffusions (AGIDs), virus neutralization assays, and enzyme-linked immunosorbent assays (ELISAs) [1,9, 11,12,16,25]. The most widely used diagnostic methods for the serological detection of BLV-specific antibodies are AGID and ELISA, which are antigen-based assays that use either wild type BLV gp51 isolated from fetal lamb kidney (FLK) cells, or a recombinant BLV antigen that is expressed in insect cells [6,16,19,23]. Although the AGID test is less sensitive and specific than ELISA, AGID test has been widely used mainly for the routine diagnosis of serum samples because of the simplicity. However, the cell line FLK/BLV, used for antigen production of AGID, is known to be contaminated with bovine viral diarrhea virus (BVDV) [2,22]. Sometimes, cross-reactivity occurred between the BVDV antibodies induced by the vaccine and BVDV in the BLV antigen preparation.

The aim of this paper is therefore to describe the production of gp51 and partial gp30 by recombinant baculovirus in insect cells. The recombinant protein was used for detection of antibodies in sera of BLV-infected cattle as AGID antigen.

Materials and Methods

Cells and viruses

FLK cells chronically infected with BLV were cultured in Eagle’s minimum essential medium containing 10% fetal bovine serum. To obtain BLV antigen for traditional AGID, FLK cell culture supernatant was collected and concentrated according to the protocol of Miller and Van Der Maaten [16].

For the cloning and expression of recombinant BLV gp51/gp30\(_{-}\), SF-9 and Hi-five cells were cultured in SF 900 II serum-free medium (Invitrogen, USA).
Cloning and expression of BLV gp51/gp30T-

Recombinant BLV gp51/gp30T- (Korean isolate, Gene bank accession AY995174), which lacked the transmembrane region of gp30 and retained the signal peptide (amino acids 1-409) was expressed. Genomic DNA was extracted from the blood of dairy cows that were naturally infected with BLV using a genomic DNA kit (Promega, USA). For the amplification of BLV gp51/gp30T- sequences, the following oligonucleotide primers were used: 5´-CTC GAG ATG CCC AAA GAA CGA CGG TC -3´, which contained a restriction enzyme site for XhoI at the 5´ end, and 5´-GCT GGA GAT CAC CGA GGC GGA -3´. The amplified DNA fragment was inserted into pGEM T-easy (Promega, USA) for sequencing. The cloned DNA fragment was then excised and ligated into the transfer vector pBacPAK8 (Clontech, USA), as shown in Fig. 1A. A translational stop codon was inserted downstream of BLV gp51/gp30T- at the PacI restriction site (5´ TAATTA 3´) of pBacPAK8 BlvGP. Recombinant viruses were purified by plaque assay and screened for the expression of BLV gp51/gp30T- by immunofluorescence assay (IFA), BLV-ELISA (indirect-ELISA), and western blot using BLV-positive bovine serum and monoclonal antibody as previously described [13-15].

Detection of recombinant BLV gp51/gp30T-

Indirect (I)-ELISA was performed as previously described [15]. Briefly, 100 μL of the supernatant from Hi-five cells infected with recombinant baculovirus and non-infected control cells were diluted 1 : 10 (2 μg/mL) in 0.05 M carbonate-bicarbonate buffer (pH 9.6). And the 96-well microplates (Maxisorp; Nunc, USA) were coated with the diluted supernatant at 4°C overnight. Plates were blocked with 10% skimmed milk (Marvel, UK) in phosphate buffered saline (PBS) at room temperature for 1 h. Subsequently, plates were washed 3 times with PBS containing 0.05% Tween 20 (PBST) and incubated with a 1 : 25 dilution of test sera, including the reference positive serum (NVSL, USA) in 10% skim milk in PBST for 1 h at 37°C. The plates were then washed 3 times with PBST. 100 μL of horseradish peroxidase labeled anti-bovine IgG (Pierce, USA) or each subclass (Serotec, UK), diluted 1 : 3,000 in PBST containing 10% skimmed milk, were then added to each well and incubated for 1 h at 37°C.

The plates were washed 3 times with PBST and developed with commercially available 3, 3´, 5, 5´-tetramethyl-benzidine (Kirkegaard & Perry Laboratories, USA). After 30 min, the reaction was stopped by adding 100 μL of 0.5 M H₂SO₄. The optical density (OD) of the solution was measured at 450 nm. The net OD of test well was calculated by the subtraction of OD from control well.

The recombinant BLV gp51/gp30T- was tested for its reactivity to an anti-gp51 MAb by western blotting. The anti-gp51 MAb were produced through the cell fusion method [29]. Briefly, the DNA fragment for BLV gp51/gp30T- was ligated with pSecTaq 2C DNA vector (Invitrogen, USA) and intramuscularly inoculated to Balb/c mice. Anti- BLV gp51/gp30T- MAbS were screened and selected by indirect ELISA. One hybridoma cell line was finally selected for Western blotting in this study.

Preparation of recombinant BLV gp51/gp30T- for AGID

For the production of recombinant BLV gp51/gp30T-, approximately 7.5 × 10⁷ Hi-five cells were infected with the recombinant virus (AcBlvGP) at a multiplicity of infection of 0.1-1, and then cultured at 27°C for 6 days. Cultures were subjected to centrifugation at 3,000 × g for...
30 min to remove cells, and then the supernatant was subjected to another round of centrifugation at 100,000 x g for 2 h. The supernatant was concentrated in a cellulose membrane (M.W. 12,000; GibcoBRL, USA) with polyethylene glycol (M.W. 8,000; Serva, Germany) for 12~18 h at room temperature. A fraction (1/100) of the initial supernatant volume was evaluated by AGID using the indicated reference sera. The concentration of recombinant antigen was determined using a BCA protein assay kit (Pierce, USA), according to the manufacturer’s instructions, and antigen was stored at −70°C until use. AGIDs were conducted as previously described [5,16,17].

**Identification of the BLV provirus**

For the detection of proviral DNA of BLV, DNA samples were prepared both from peripheral blood mononuclear cells (PBMCs) and whole blood by using commercially available DNA extraction Kit (Promega, USA). The first and nested PCR for proviral DNA of BLV was conducted according to the protocols described previously [1,17].

**Animals and sera**

A dairy cow (Holstein) that was naturally infected with BLV in the field was obtained from a farm in Korea. The cow was fertilized naturally, and the calf was placed in conventional housing with the dam, and monitored for the presence of BLV-specific antibodies, as previously described [24,26,27]. Whole blood samples and sera were collected at 3-week intervals.

The reference bovine sera (strong BLV-positive serum and negative serum) were purchased from National Veterinary Services Laboratories (USA). Two hundred and ten bovine serum samples that were collected at four slaughterhouses throughout Korea from 2003 to 2004 were also analyzed. The collected field sera were stored at −20°C until use.

**Diagnostic AGID**

AGIDs were conducted according to the standard procedure recommended by the Office International des Epizooties [17]. Briefly, gel diffusion plates consisting of 0.8% noble agar and 8.5% NaCl were allowed to stand at room temperature for 72 h before obtaining a reading. All test sera were initially screened by AGID using baculovirus-expressed BLV gp51/gp30T- and FLK-derived BLV antigen. Sera were also tested using a commercially available ELISA kit (IDEXX, USA).

**Data analysis**

Calculations to determine test sensitivity and specificity were carried out as previously described [5]. Sensitivity and specificity were calculated according to the following equations:

\[
\text{% sensitivity} = \frac{\text{positive by both methods}}{\text{positive by both methods} + \text{positive by the standard}} \times 100
\]

\[
\text{% specificity} = \frac{\text{negative by both methods}}{\text{negative by both methods} + \text{negative by the standard}} \times 100
\]

**Results**

**Expression of recombinant BLV gp51/gp30T-**

DNA fragment for BLV gp51/gp30T- of BLV was amplified by PCR and the PCR product was inserted into the pGEM T-easy vector for sequencing. The nucleotide sequence of the amplified BLV gp51/gp30T- gene was compared with the previously published sequence (Gene bank accession AF503581) [28]. The sequence of BLV gp51/gp30T- showed 95.5% nucleotide identity and 96.0% amino acid identity, respectively (data not presented here). The BLV gp51/gp30T- fragment was ligated with pBacPAK8 by using Xho I and Xho I restriction sites (Fig. 1A). After cotransfection with viral DNA and pBacPAK8 BLV gp51/gp30T- into SF-9 cells, recombinant clones were screened for the expression of BLV gp51/gp30T- by IFA and indirect-ELISA using positive bovine serum as indicated in Figs. 1B and 2. However, when the expressed cells and supernatant were compared at the same time by I-ELISA with positive bovine serum, the OD from the culture media was 10 times higher than the cells, showing that the expressed BLV gp51/gp30T- was secreted from the expressed cells (Fig. 2A). In fact, a time course experiment indicated that the recombinant BLV gp51/gp30T- was secreted outside of the expressed cells in 24 h and retained up to 120 h post inoculation in the supernatant indicating that it would be possible to prepare the recombinant BLV gp51/gp30T- by simple purification methods as shown in Fig. 2B. In addition, it was possible to detect the expressed BLV gp51/gp30T-, with a molecular weight of 62 kDa, from the supernatant with anti-gp51 MAb by western blotting as expected (Fig. 1C).

**BLV diagnosis using recombinant BLV gp51/gp30T-**

The AGID diagnostic potential was examined using recombinant BLV gp51/gp30T- as the antigen. The new antigen was serially diluted in duplicate and determined minimum concentration (data not present here). The minimum concentration was able to detect 0.3 mg/mL of BLV gp51/gp30T-. (Fig. 2). The AGID results using recombinant BLV gp51/gp30T- were reproducible and consistent, and there were no significant variations in repeated tests. In the diagnostic AGIDs of a calf born to a BLV-infected mother, recombinant BLV gp51/gp30T yielded positive results at an earlier time point than the traditional antigen. The BLV antigen was detected the calf’s whole blood by PCR (Table 1).
Fig. 2. Expression of recombinant BLV gp51/gp30r in expressed cells and supernatant. (A) Comparison of recombinant BLV gp51/gp30r between expressed cells and supernatant by indirect enzyme-linked immunosorbent assay (I-ELISA) using reference positive (ST+) and negative (N) bovine sera. A: Hi-five cells only (infected), B: Supernatant from expressed cells, C: Control cells, D: Supernatant (control). The results were expressed as optical density (OD) value at 5 days post inoculation (DPI). (B) Time course profiles of recombinant BLV gp51/gp30r secretion from the expressed Hi-five cells by I-ELISA using reference positive bovine serum (*25). The results were expressed as the OD value at 5 DPI.

Table 1. Diagnosis of bovine leukemia virus (BLV) using agar gel immunodiffusion (AGID) and PCR from a congenitally infected calf

| Weeks after delivery | 9  | 12  | 15  | 18  | 21  | 24  | 27  | 30  | 33  | 36  | 39  | 42  | 45  | 48  | 51  | 54  |
|----------------------|----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| AGID                 |    |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
| Antigen from BLV-infected FLK* cell | -  | -   | -   | -   | -   | -   | -   | -   | -   | -   | -   | +   | +   | +   | +   | +   |
| Recombinant gp51 & gp30r protein | -  | -   | -   | -   | -   | -   | -   | -   | -   | -   | -   | -   | -   | -   | -   | -   |
| Proviral First PCR   | -  | -   | -   | -   | -   | -   | -   | -   | -   | -   | -   | -   | -   | -   | -   | -   |
| DNA Nested PCR       | -  | -   | -   | -   | -   | +   | +   | +   | +   | +   | +   | +   | +   | +   | +   | +   |

*FLK: fetal lamb kidney.

Field analysis of BLV antibody detection by AGID

A field evaluation of 210 serum samples was performed to determine the diagnostic efficiency of AGID using either recombinant baculovirus-expressed BLV gp51/gp30r or traditional FLK-derived antigen. The same samples were analyzed using a commercially available diagnostic ELISA (IDEXX, USA). AGID using the recombinant BLV gp51/gp30r detected 31 positive samples from a total of 43 positive sera (Table 2), whereas using the FLK-derived antigen detected 29 positive samples. The negative number for the recombinant is 179 (12 plus 167) and the negative number for the FLK is 181 (14 plus 167).

The diagnostic efficiencies of traditional and recombinant antigen-based AGIDs were compared to a commercially available BLV-ELISA. AGID using recombinant BLV gp51/gp30r and traditional antigen had a relative sensitivity of 69.8% and 67.4%, respectively, and a relative specificity of 93.3% and 92.3% (Table 2). Overall, recombinant BLV gp51/gp30r was more sensitive than the traditional FLK

Fig. 3. Agar gel immunodiffusion with recombinant BLV gp51/gp30r- and fetal lamb kidney (FLK)-derived BLV antigen. The minimum concentration was able to detect 0.3 mg/mL of this recombinant antigen. Ab, positive bovine reference serum (center well); F, FLK-derived BLV antigen (3 mg/mL); 1-3, recombinant BLV gp51 & gp30r r; (1) 0.5; (2) 0.38 and (3) 0.3 mg/mL, respectively.
Table 2. Comparison of different AGID antigens between BLV-infected (n = 43) and non-infected (n = 167) animals as previously determined by IDEXX ELISA Kits

| Infection status | FLK-derived antigen | Recombinant gp51/gp30T- antigen |
|------------------|---------------------|---------------------------------|
| (IDXX ELISA)     | Positive            | Negative                        |
| BLV-infected (43)| 29                  | 14                              |
| BLV non-infected (167) | 0             | 167                             |
| BLV-infected (43)| 31                  | 12                              |
| BLV non-infected (167) | 0             | 167                             |

Discussion

BLV gp51 and the BLV viral capsid protein (core protein, p24) are the immunodominant viral proteins in vivo. For this reason, the expression and purification of BLV gp51 for use as an antigenic reagent represents a promising approach to the development of diagnostic assays, as well as vaccines [6,21]. BLV env encodes a single precursor protein cleaved into two subunits; the outer membrane protein, gp51, and the transmembrane subunit, gp30. BLV gp51 is the major envelope glycoprotein, whereas gp30 contains an N-terminal fusion domain that participates in syncytium formation along with gp51, as well as a transmembrane domain [8,10,20,28]. In the current study, we have described the expression of recombinant gp51/gp30T- using a baculovirus expression system, in which the C-terminal transmembrane domain of p30 is lacking, and the purification of BLV gp51/gp30T- for use as a diagnostic antigen.

In contrast to BLV gp51, the BLV Env precursor protein is not secreted when it is expressed in insect cells [6,21]. In the current study, to eliminate the risk of antigen being retained in cells, we generated an env expression construct that encoded gp51 and the N-terminal region of gp30 lacking the C-terminal cytoplasmic domain and we demonstrated that BLV gp51/gp30T- was secreted from insect cells.

The FLK cell line is still the primary cell line used for BLV antigen production for commercial diagnostic tests. As this cell line is known to be contaminated with BVDV, the contamination may result in additional diagnostic problems concerning the specificity of the reactions [2,22].

Compared to the traditional production of BLV antigen derived from infected FLK cells, the current method is similar to previously described methods in that it is both simple and rapid [5]. Crude BLV gp51/gp30T- preparations were generated within a day from supernatants of spin-cultured insect cells, and provided sufficient antigen for more than 2,000 samples in a volume of 500 ml. There was no risk of adventitious viral contamination, as in the case with BVDV, and a low rate of variability from batch to batch might be achievable because of the simplicity in preparing AGID antigen. Furthermore, when we analyzed serum from a calf born to an infected mother, AGID with recombinant BLV gp51/gp30T- yielded positive results at an earlier time point than traditional AGID using FLK-BLV antigen. Recombinant BLV antigen proved to be more sensitive than the FLK/BLV antigen (by 2.4%). Overall, there was an increase in both in sensitivity and specificity in field tests of sera using recombinant BLV antigen, providing additional support for the use of recombinant BLV gp51/gp30T- as an alternative diagnostic antigen.

Acknowledgments

We would like to thank Dr. Carl A. Gagnon, University of Montreal, Canada for his careful review and advice on this manuscript. This project was supported by a grant from the National Veterinary Research and Quarantine Service, Korea.

References

1. Ballagi-Pordány A, Klintevall K, Merza M, Klingeborn B, Belák S. Direct detection of bovine leukemia virus infection: practical applicability of a double polymerase chain reaction. Zentralbl Veterinarmed B 1992, 39, 69-77.
2. Beier D, Riebe R, Blankenstein P, Starick E, Bondzio A, Marquardt O. Establishment of a new bovine leukemia virus producing cell line. J Virol Methods 2004, 121, 239-246.
3. Callebaut I, Vonèche V, Mager A, Fumièré O, Krchnak V, Merza M, Zavada J, Manmerickx M, Burny A, Portetelle D. Mapping of B-neutralizing and T-helper cell epitopes on the bovine leukemia virus external glycoprotein gp51. J Virol 1993, 67, 5321-5327.
4. Chi J, VanLeeuwen JA, Weersink A, Keefe GP. Direct production losses and treatment costs from bovine viral diarrhea virus, bovine leukemia virus, Mycobacterium avium subspecies paratuberculosis, and Neospora caninum. Prev Vet Med 2002, 55, 137-153.
5. Choi KY, Liu RB, Buchring GC. Relative sensitivity and specificity of agar gel immunodiffusion, enzyme immunosorbent assay, and immunoblotting for detection of anti-bovine...
leukemia virus antibodies in cattle. J Virol Methods 2002, 104, 33-39.
6. De Giuseppe A, Feliziani F, Rutili D, De Mia GM. Expression of the bovine leukemia virus envelope glycoprotein (gp51) by recombinant baculovirus and its use in an enzyme-linked immunosorbent assay. Clin Diagn Lab Immunol 2004, 11, 147-151.
7. Doménech A, Llamés I, Goyache J, Suárez G, Gómez-Lucía E. Macrophages infected with bovine leukemia virus (BLV) induce humoral response in rabbits. Vet Immunol Immunopathol 1997, 58, 309-320.
8. Gatei MH, Good MF, Daniel RC, Lavin MF. T-cell responses to highly conserved CD4 and CD8 epitopes on the outer membrane protein of bovine leukemia virus: Relevance to vaccine development. J Virol 1993, 67, 1796-1802.
9. Johnson M, Rommel F, Moné J. Development of a syncytia inhibition assay for the detection of antibodies to bovine leukemia virus in naturally infected cattle; comparison with Western blot and agar gel immunodiffusion. J Virol Methods 1998, 70, 177-182.
10. Johnston ER, Radke K. The SU and TM envelope protein subunits of Bovine leukemia virus are linked by disulfide bonds, both in cells and in virions. J Virol 2000, 74, 2930-2935.
11. Kittelberger R, Reichel MP, Meynell RM, Tham KM, Molloy JB. Detection of antibodies against the core protein p24 of the bovine leukemia virus in cattle for confirmatory serological testing. J Virol Methods 1999, 77, 109-114.
12. Kuckleburg CJ, Chase CC, Nelson EA, Marras SA, Dammen MA, Christopher-Hennings J. Detection of bovine leukemia virus in blood and milk by nested and real-time polymerase chain reactions. J Vet Diagn Invest 2003, 15, 72-76.
13. Kweon CH, Ko YJ, Kim WI, Lee SY, Nah JJ, Lee KN, Sohn HJ, Choi KS, Hyun BH, Kang SW, Joo YS, Lubroth J. Development of a foot-and-mouth disease NSP ELISA and its comparison with differential diagnostic methods. Vaccine 2003, 21, 1409-1414.
14. Kweon CH, Kwon BJ, Kim IJ, Lee SY, Ko YJ. Development of monoclonal antibody-linked ELISA for sero-diagnosis of vesicular stomatitis virus (VSV-IN) using baculovirus expressed glycoprotein. J Virol Methods 2005, 130, 7-14.
15. Kweon CH, Kwon BJ, Ko YJ, Kenchi S. Development of competitive ELISA for serodiagnosis on African horsesickness virus using baculovirus expressed VP7 and monoclonal antibody. J Virol Methods 2003, 113, 13-18.
16. Miller JM, Van Der Maaten MJ. Use of glycoprotein antigen in the immunodiffusion test for bovine leukemia virus antibodies. Eur J Cancer 1977, 13, 1369-1375.
17. Office International des Epizooties (OIE). Manual of Diagnostic Tests and Vaccines for Terrestrial Animals. Chapter 2.3.4. OIE, Paris, 2004.
18. Portetelle D, Dandoy C, Burny A, Zavada J, Siakkou H, Gras-Masse H, Drobecq H, Tartar A. Synthetic peptides approach to identification of epitopes on bovine leukemia virus envelope glycoprotein gp51. Virology 1989, 169, 34-41.
19. Portetelle D, Mammericks M, Burny A. Use of two monoclonal antibodies in an ELISA test for the detection of antibodies to bovine leukemia virus envelope protein gp51. J Virol Methods 1989, 23, 211-222.
20. Reichert M, Winnicka A, Willems L, Kettmann R, Cantor GH. Role of the proline-rich motif of bovine leukemia virus transmembrane protein gp30 in viral load and pathogenicity in sheep. J Virol 2001, 75, 8082-8089.
21. Russo S, Montermini L, Berkovitz-Siman-Tov R, Ponti W, Poli G. Expression of bovine leukemia virus ENV glycoprotein in insect cells by recombinant baculovirus. FEBS Lett 1998, 436, 11-16.
22. Simard C, Richardson S, Dixon P, Komal J. Agar gel immunodiffusion test for the detection of bovine leukemia virus antibodies: lack of trans-Atlantic standardization. Can J Vet Res 2000, 64, 96-100.
23. Trono KG, Pérez-Filgueira DM, Duffy S, Borca MV, Carrillo C. Seroprevalence of bovine immunodeficiency virus in dairy cattle in Argentina: comparison of sensitivity and specificity of different detection methods. Vet Microbiol 2001, 83, 235-248.
24. Usui T, Meas S, Konnai S, Ohashi K, Onuma M. Seroprevalence of bovine immunodeficiency virus and bovine leukemia virus in dairy and beef cattle in Hokkaido. J Vet Med Sci 2003, 65, 287-289.
25. Van den Heuvel M, Portetelle D, Jefferson B, Jacobs RM. Adaptation of a sandwich enzyme-linked immunosorbent assay to determine the concentration of bovine leukemia virus p24 and optimal conditions for p24 expression in short-term cultures of peripheral blood mononuclear cells. J Virol Methods 2003, 111, 61-67.
26. Van der Maaten MJ, Miller JM, Schmerr MJ. In utero transmission of bovine leukemia virus. Am J Vet Res 1981, 42, 1052-1054.
27. Van der Maaten MJ, Miller JM, Schmerr MJ. Effect of castral antibody on bovine leukemia virus infection of neonatal calves. Am J Vet Res 1981, 42, 1498-1500.
28. Willems L, Gatot JS, Mammericks M, Portetelle D, Burny A, Kerkhofs P, Kettmann R. The YXXL signalling motifs of the bovine leukemia virus transmembrane protein are required for in vivo infection and maintenance of high viral loads. J Virol 1995, 69, 4137-4141.
29. Yokoyama WM. Production of monoclonal antibodies. Curr Protoc Cytom 2006, Appendix 3, Appendix 3J.